Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients
- 55 Downloads
Prediction of survival endpoints, e.g., overall survival (OS) and progression-free survival (PFS), based on early observations, i.e., tumor size, may facilitate early decision making in oncology drug development. In this paper, using data from six randomized trials for first- or second-line advanced breast cancer (ABC) treatments with various mechanisms of action, tumor size change from baseline at different observation time points was evaluated as a predictor for survival endpoints using different modeling approaches. The aim is to establish a predictive model where tumor size change from baseline can be used as a treatment independent predictive marker for PFS and OS in first- and second-line ABC. The results showed that tumor size change at single time point (TSP) or up to certain time points as a time-varying covariate (TSTVC) were significant predictors for OS and PFS in the survival models along with other covariates identified for each line of treatment. TSP and TSTVC models performed similarly for first-line treatments; TSTVC performed significantly better for second-line treatments. Eight weeks was selected as the recommended early evaluation time of tumor size change to predict OS and PFS in both first- and second-line treatment, while better prediction can be achieved for first-line OS by using 16 weeks tumor size change. The result of this study is treatment independent and can be used to predict the outcome of the clinical trials using early readout of tumor size change for the classes of drugs that have been evaluated in this study.
KEY WORDSbreast cancer OS PFS time-varying tumor size
This study was sponsored by Pfizer. Editorial support was provided by Complete Healthcare Communications, LLC (West Chester, PA), a CHC Group company, and was funded by Pfizer.
Compliance with Ethical Standards
Conflict of Interest
K.P. and D.W. are employees of and shareholders of Pfizer Inc. W.S. was a former employee of Pfizer and a current shareholder of Pfizer Inc. H.-S.L. was a research fellow with Pfizer when this research was conducted.
- 6.Bruno R, et al. Simulations to assess phase II noninferiority trials of different doses of capecitabine in combination with docetaxel for metastatic breast cancer. CPT Pharmacometrics Syst Pharmacol. 2012;1(1):6.Google Scholar
- 9.US Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medicinal products. Silver Spring, MD: US Department of Health and Human Services, US Food and Drug Administration; 2004.Google Scholar
- 10.European Medicines Agency. Road map to 2015. London, UK: European Medicines Agency; 2010.Google Scholar
- 12.Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30:921–9.CrossRefGoogle Scholar
- 24.Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. 6, 1076–1087 (1988).Google Scholar